Fate Therapeutics Inc. (FATE) Research Coverage Started at Roth Capital
Equities research analysts at Roth Capital assumed coverage on shares of Fate Therapeutics Inc. (NASDAQ:FATE) in a research report issued on Thursday. The firm set a “buy” rating on the biopharmaceutical company’s stock.
Several other brokerages have also recently weighed in on FATE. BMO Capital Markets set a $4.00 price objective on shares of Fate Therapeutics and gave the stock a “buy” rating in a research note on Monday, August 8th. HC Wainwright reissued a “buy” rating on shares of Fate Therapeutics in a research note on Tuesday, August 9th. Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Thursday, August 11th. Finally, Leerink Swann restated an “outperform” rating and issued a $4.00 target price on shares of Fate Therapeutics in a report on Tuesday, June 21st. Nine analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $6.29.
Fate Therapeutics (NASDAQ:FATE) opened at 3.18 on Thursday. The company’s market cap is $91.88 million. The stock has a 50 day moving average price of $2.65 and a 200 day moving average price of $2.03. Fate Therapeutics has a one year low of $1.46 and a one year high of $7.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/fate-therapeutics-inc-fate-research-coverage-started-at-roth-capital.html
Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.03. Fate Therapeutics had a negative net margin of 699.10% and a negative return on equity of 90.94%. The company had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $1.02 million. On average, equities analysts anticipate that Fate Therapeutics will post ($1.12) EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in the stock. Redmile Group LLC raised its position in shares of Fate Therapeutics by 1.0% in the second quarter. Redmile Group LLC now owns 1,502,180 shares of the biopharmaceutical company’s stock valued at $2,554,000 after buying an additional 15,200 shares in the last quarter. Lombard Odier Asset Management USA Corp raised its position in shares of Fate Therapeutics by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 256,426 shares of the biopharmaceutical company’s stock valued at $436,000 after buying an additional 7,052 shares in the last quarter. Board of Trustees of The Leland Stanford Junior University bought a new position in shares of Fate Therapeutics during the second quarter valued at $495,000. BlackRock Fund Advisors raised its position in shares of Fate Therapeutics by 26.2% in the second quarter. BlackRock Fund Advisors now owns 75,572 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 15,701 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Fate Therapeutics by 3.5% in the second quarter. Vanguard Group Inc. now owns 657,573 shares of the biopharmaceutical company’s stock valued at $1,118,000 after buying an additional 22,098 shares in the last quarter. Hedge funds and other institutional investors own 48.71% of the company’s stock.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.